A Phase II study evaluated the efficacy of SG001 (Enlonstobart Injection) in patients with PD-L1-positive recurrent/metastatic cervical cancer, enrolling a total of 107 patients with a median follow-up of 14.0 months. The gene discussed is CD274; the disease is cervical cancer.